Cyproterone to treat aggressivity in dementia: a clinical case and systematic review

  title={Cyproterone to treat aggressivity in dementia: a clinical case and systematic review},
  author={Blanca M Bolea-Alamanac and Simon J C Davies and David M. Christmas and Hazel Baxter and Sarah Cullum and David J. Nutt},
  journal={Journal of Psychopharmacology},
  pages={141 - 145}
Aggressivity is a common problem in the management of elderly patients with dementia. Medications currently used to diminish aggressive behaviour in dementia can have problematic side effects. We present a case and systematic review of the current knowledge about the use of cyproterone acetate to treat aggressivity (excluding hypersexuality related behaviours) in dementia. An 82-year-old man required psychiatric inpatient admission due to agitation and aggressivity and was diagnosed with… Expand
Cyproterone acetate as a treatment for moderate‐to‐severe inappropriate sexual behavior in dementia
CPA is an effective and safe pharmacological approach to reduce moderate-to-severe ISB in older patients with dementia and can be used to control aggression (excluding hypersexuality-related behaviors) in dementia. Expand
Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia
This algorithm-based approach for drug treatment of agitation/aggression in Alzheimer’s/mixed dementia has been implemented in several Canadian Hospital Inpatient Units and impact should be assessed in future research. Expand
Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews
New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade. Expand
Double-Blind, Placebo-Controlled Trial of Cyproterone Acetate to Prevent Flare-Up Effect on Dogs Implanted With Deslorelin
It is suggested that cyproterone acetate is effective and safe to supress the deslorelin induced behavioral flare-up effect, but not the rise in testosterone. Expand
A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia.
The evidence for clinical effectiveness and cost-effectiveness of non-pharmacological interventions for reducing agitation in dementia, considering dementia severity, the setting, the person with whom the intervention is implemented, whether the effects are immediate or longer term, is reviewed. Expand
Interpreting molecular similarity between patients as a determinant of disease comorbidity relationships
A disease interaction network inferred from similarities between patients’ molecular profiles is built, which significantly recapitulates epidemiologically documented comorbidities and discoveries in patient subgroups are discovered. Expand
Evidence-based medicine in geriatrics
Ouderen zijn namelijk vaak uitgesloten van klinische studies omdat ze bijvoorbeeld teveel comorbiditeit hebben, maar ook soms zonder duidelijke reden het beste door artsen die met ouderen werken in de klinisch praktijk kan worden toegepast. Expand
Drugs to Treat Dementia


[Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia].
A detailed clinical analysis is required to avoid the use of cyproterone in non-aggressive and non-impulsive patients, and a randomized double-blind study should be carried out in the near future. Expand
Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study.
Cyproterone showed significantly better efficacy and safety than haloperidol in controlling mild aggression associated with AD and additional research is needed to confirm if these results can be ratified in a larger study and generalized to patients whose aggression is more severe. Expand
Normalization of sexual behaviour in a female with dementia after treatment with cyproterone
Compulsive behaviours can be a feature of different psychiatric diseases but overt hypersexuality is nevertheless a rare condition in females, especially in the absence of endocrinologicalExpand
Atypical Antipsychotics in Elderly Patients with Dementia or Schizophrenia: Review of Recent Literature
A careful consideration of the risk‐benefit ratio of atypical antipsychotics, as well as that of available alternative treatments, is needed for each individual elderly patient. Expand
Antiandrogen Treatment of Aggressivity in Men Suffering from Dementia
  • M. Amadeo
  • Medicine
  • Journal of geriatric psychiatry and neurology
  • 1996
Three demented patients who manifested an aggressive syndrome and motor disturbances including agitation, pacing, and restlessness received a therapeutic trial of the antiandrogen agentsExpand
Diagnosis and management of dementia with Lewy bodies
The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. Expand
Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients
Among elderly patients, the risk of death associated with conventional antipsychotic medications is comparable to and possibly greater than therisk of deathassociated with atypical antipsychotics medications. Expand
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium
It could be more appropriate, for a consensus statement, to conclude that finding EEG abnormalities does not exclude the diagnosis of LBD, instead of asserting that EEG abnormalities support LBD diagnosis. Expand
Self-Injurious Behavior Is Decreased by Cyproterone Acetate in Adult Male Rhesus (Macaca mulatta)
CA was a partially effective treatment for adult male macaques whose behavioral problems include SIB, and it was hypothesized that the progestin activity of CA represses the hypothalamic gonadal axis and decreases testosterone, which in turn decreases SIB. Expand
Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience.
Cyproterone acetate (CPA) leads to loss of libido and the ability to achieve erection, followed by the inability to achieve orgasm, after about 14 days of treatment, and is generally well tolerated. Expand